The impact of early direct-contact experiences on reducing mental health stigma among student pharmacists: A pilot study

The impact of early direct-contact experiences on reducing mental health stigma among student pharmacists: A pilot study

Introduction Mental health–related stigma is a barrier to treatment and recovery for serious mental illnesses (SMIs). Educational training programs demonstrate positive changes in health professional students’ attitudes and stigma toward SMI; however, student pharmacists have minimal opportunity to...

Full description

Bibliographic Details
Main Authors:	Amber R. Tran, BS, Saumyaa A. Patel, BS, Lindsey J. Loera, PharmD, Tawny Smith, PharmD, BCPP, Samantha Catanzano, PharmD, BCPP
Format:	Article
Language:	English
Published:	American Association of Psychiatric Pharmacists 2024-02-01
Series:	Mental Health Clinician
Subjects:	serious mental illness stigma experiential education pharmacy student psychiatry mental health
Online Access:	https://theijpt.org/doi/pdf/10.9740/mhc.2024.02.073

Similar Items

COVID-19 reinfection in a patient with a serious mental illness within a long-term inpatient psychiatric care hospital
by: Brianna Englett, PharmD, BCPP, et al.
Published: (2021-09-01)

Depression-related stigma among primary care providers
by: Andrew Kluemper, PharmD, BCPS, BCPP, et al.
Published: (2021-05-01)

Adverse childhood experiences among California student pharmacists
by: Shawn R. Smith, PharmD, APh, et al.
Published: (2024-02-01)

Positioning psychiatric pharmacists to improve mental health care
by: Julie A. Dopheide, PharmD, BCPP, FASHP, et al.
Published: (2022-04-01)

Systematic literature review of the impact of psychiatric pharmacists
by: Jessica L. Ho, PharmD, BCPP, BCPS, et al.
Published: (2024-02-01)

Increasing access to psychiatric care during the COVID-19 pandemic through mental health clinical pharmacy specialist services
by: Vickery P. Brittany PharmD, BCPS, BCPP, CPP, et al.
Published: (2023-08-01)

Antipsychotic factors related to time to competency for forensic inpatients in a state psychiatric facility
by: Amber Lemons, PharmD, BCPP, et al.
Published: (2022-06-01)

Best practice model for outpatient psychiatric pharmacy practice, part 1: Development of initial attribute statements
by: Richard J. Silvia, PharmD, BCPP, et al.
Published: (2022-04-01)

Addition of a clinical pharmacist practitioner to an inpatient addiction triage team and related medication outcomes
by: Kim Ehrhard, PharmD, BCPP, et al.
Published: (2023-08-01)

Antipsychotics in child and adolescent patients with major depressive disorder: A retrospective analysis of prescribing patterns
by: Danielle Dauchot, PharmD, et al.
Published: (2024-02-01)

Social stigma and mental health
by: M. ValverDe Barea, et al.
Published: (2021-04-01)

Publication rates and characteristics of PGY2 psychiatric pharmacy resident research projects
by: Dayton L. Antley, PharmD, BCPS, BCPP, et al.
Published: (2023-01-01)

Impact of a pharmacist-driven tardive dyskinesia screening service
by: Niyati Butala, PharmD, BCPP, et al.
Published: (2021-07-01)

A Veterans Affairs' perspective in response to Best Practice Model Subcommittee attribute statements for outpatient psychiatric pharmacists
by: Jonathan F. Lister, PharmD, BCPP, et al.
Published: (2022-11-01)

Impact of marketing to improve patient access to care and clinic utilization for clinical pharmacy specialists
by: Nora Bairagdar, PharmD, BCPS, et al.
Published: (2023-03-01)

Best practice model for outpatient psychiatric pharmacy practice, part 2: Confirmation of the attribute statements
by: Kelly C. Lee, PharmD, MAS, BCPP, et al.
Published: (2022-04-01)

Impact of Board Certified Psychiatric Pharmacists on improving urinary tract infection antibiotic appropriateness at an acute psychiatric hospital
by: Hamad Mohammad Adam PharmD, BCPS, et al.
Published: (2023-10-01)

Factors influencing performance on the Board Certified Psychiatric Pharmacist Examination: Passing rates and domain-level scores
by: Timothy J. Muckle, PhD, et al.
Published: (2021-11-01)

Long-term use of antidepressants, mood stabilizers, and antipsychotics in pediatric patients with a focus on appropriate deprescribing
by: Danielle L. Stutzman, PharmD, BCPP
Published: (2021-11-01)

Coping, resilience, and emotional well-being in pharmacy students during the COVID-19 pandemic
by: Andrea V. Fuentes, PharmD, et al.
Published: (2021-09-01)

Antidepressant prescribing in transgender and nonbinary individuals diagnosed with gender dysphoria and mood or anxiety disorders
by: Casey M. Tiefenthaler, PharmD, BCPP, et al.
Published: (2023-12-01)

Assessing Mental Illness Stigma: A Complex Issue
by: Stefania Mannarini, et al.
Published: (2019-01-01)

An innovative approach to teaching depression and anxiety medication management: Virtual choose your own adventure, psychiatry edition
by: Nina Vadiei, PharmD, BCPP, et al.
Published: (2023-08-01)

Effect of cannabis use on PTSD treatment outcomes in veterans
by: Meagan Petersen, PharmD, BCPP, et al.
Published: (2021-07-01)

Survey of prescriptive authority among psychiatric pharmacists in the United States
by: Kelly C. Lee, PharmD, MAS, APh, BCPP, FCCP, et al.
Published: (2023-03-01)

Development and implementation of a physician-pharmacist collaborative practice model for provision and management of buprenorphine/naloxone
by: Lindsay M. Mailloux, PharmD, et al.
Published: (2021-01-01)

Serotonin syndrome and neuroleptic malignant syndrome: A case report of intersecting symptomatology
by: Loulwa Maktabi, PharmD, BCPS, et al.
Published: (2024-02-01)

Pharmacist impact on medication reconciliation of behavioral health patients boarding in the emergency department
by: Mary Accomando, PharmD, BCPP, et al.
Published: (2022-06-01)

Reducing the stigma of mental illness
by: H. Stuart
Published: (2016-01-01)

Evaluation of intramuscular olanzapine and ziprasidone in the medically ill
by: Seema M. Patel, PharmD, BCPP, et al.
Published: (2021-01-01)

Impact of traditional versus nontraditional initiation dosing schedule of paliperidone palmitate on 30-day readmission and safety
by: Erika Kim, PharmD, BCPP, et al.
Published: (2023-12-01)

Closing the gap: Raising medical professionals' transgender awareness and medical proficiency through pharmacist-led education
by: Ardsley P. Congdon III, PharmD, BCPS, BCPP, et al.
Published: (2021-01-01)

Clinical pharmacist intervention to ensure safe stimulant prescribing practices at a Veterans Affairs facility
by: Bailey B. Bass, PharmD, BCPS, et al.
Published: (2024-02-01)

Comparison of antipsychotic prescribing practices following failure of antipsychotic monotherapy in the acute care setting
by: Kaitlyn Morgan, PharmD, BCPP, et al.
Published: (2023-01-01)

The effects of concurrent oral paliperidone or risperidone use with paliperidone long-acting injection
by: Trevor A. Stump, PharmD, BCPP, et al.
Published: (2021-01-01)

Attitudes of Canadian psychiatry residents if mentally ill: awareness, barriers to disclosure, and help-seeking preferences
by: Tariq Mahmood Hassan, et al.
Published: (2016-10-01)

Comparison of clozapine doses and tolerability in patients with and without concurrent valproic acid
by: Ranel Troy Santos, PharmD, BCPP, et al.
Published: (2023-01-01)

Characterization of inpatient care for patients admitted to a psychiatric hospital with a home opioid prescription
by: Kei Takamura, PharmD, BCPS, BCPP, et al.
Published: (2023-03-01)

Specialty pharmacist integration into an outpatient neurology clinic improves pimavanserin access
by: Sabrina Livezey, PharmD, CSP, et al.
Published: (2021-05-01)

Evaluating Pennsylvania Pharmacists’ Provision of Community-based Patient Care Services to Develop a Statewide Practice Network
by: Maria A. Osborne, PharmD, et al.
Published: (2011-01-01)